Principaux résultats d’HELIOS-B, étude de phase 3 évaluant le vutrisiran chez les patients atteints d’amylose à transthyrétine avec cardiomyopathie
M.D. Fontana(The Royal Free Hospital), Matthew J. Maurer(Mayo Clinic in Arizona), Joshua R. Vest(Regenstrief Institute), Olivier Huttin, Scott D. Solomon(Brigham and Women's Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Pablo García‐Pavía(Universidad Francisco de Vitoria), Dorothee Meer(University Medical Center Groningen), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Mayo Clinic in Arizona), Nobuhiro Tahara(British Heart Foundation), Antoine Fraix(Centre Hospitalier Régional et Universitaire de Nancy), Long Yang(Alnylam Pharmaceuticals (United States)), Ronald Witteles(Alnylam Pharmaceuticals (United States)), Satish A. Eraly(British Heart Foundation), John L. Berk(Boston University)
Cited by 0
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k